Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1524-4725.2012.02499.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Super-delayed-phase imaging on gadoxetic acid-enhanced MRI: do we need it? Are there other alternatives for improving liver parenchymal enhancement?
Eur Radiol
January 2025
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
Eur Respir J
January 2025
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Reply to: Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
Eur Respir J
January 2025
Center for Congenital Heart Diseases, Paediatric and Congenital Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Addressing STIs through managed care: opportunities in Medicaid and beyond.
Am J Manag Care
December 2024
Department of Health Policy and Management, George Washington University School of Public Health, 950 New Hampshire Ave NW, Washington, DC 20037. Email:
The US is facing a growing epidemic of sexually transmitted infections (STIs), with over 2.5 million cases of chlamydia, gonorrhea, and syphilis reported in 2021 and again in 2022. This public health crisis disproportionately affects youth and racial and ethnic minority communities, exacerbating barriers to accessing sexual health services.
View Article and Find Full Text PDFOverlap Syndrome (COPD and OSA): A Treatable Trait for Triple Treatment?
Pulm Ther
January 2025
MSc Program in Sleep Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient is referred to as overlap syndrome (OS). Patients with OS suffer more frequently from cardiovascular disease (CVD) and carry a higher risk of COPD-related exacerbations than patients with COPD alone, especially when OSA is left untreated. Based on recent evidence, triple therapy, namely inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-agonist (ICS-LABA-LAMA), is a treatment strategy in COPD patients with a history of exacerbations and/or CVD comorbidity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!